Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 5Terminated 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Plasma cell 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Neoplasm Metastasis 1Metastatic Castrate Resistant Prostate Cancer 1

Interventions

Docetaxel 69pembrolizumab 48Prednisone 43Nivolumab 40enzalutamide 38Gemcitabine 37Sunitinib 36Cyclophosphamide 29Radiotherapy 26Magnetic Resonance Spectroscopy 26Leuprolide 25Abiraterone Acetate 25Sorafenib 23Everolimus 23Cisplatin 23bicalutamide 19atezolizumab 18Carboplatin 18Bevacizumab 18avelumab 17Radiosurgery 17Goserelin 17Interleukin-2 16abiraterone 15fludarabine 14Doxorubicin 14olaparib 13durvalumab 13cabozantinib 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × tasquinimod × Genitourinary × Clear all
NCT02057666 2021-04-23

TasQ003

Ipsen

Phase 3 Terminated
146 enrolled 13 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT01732549 2019-11-22

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Ipsen

Phase 2 Terminated
144 enrolled 22 charts
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡